Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. While popular drugs like Ozempic and Wegovy are ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Shares of Google parent Alphabet slump after quarterly revenue misses analysts’ expectations, AMD’s data-center revenue ...

The Pseudobatch transformation is a method to easy analysis of measurement from a fed-batch fermentation process. After transformation, the data can be analysed as if it was obtained from a batch ...

Novo Nordisk hopes the new treatment can build on the success of its flagship obesity drug, Wegovy. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this ...

Novo Nordisk describes its latest work as "a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration." ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial. Shares were 10 ...